Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder
Status:
Withdrawn
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable
antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in
patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent,
will lead to improved cognition, increased wakefulness, and decreased weight in patients with
schizophrenia who are on stable antipsychotic regimens